PL3805243T3 - Pochodne androstanowe posiadające aktywność jako czyste lub w przeważającym stopniu czyste stymulatory SERCA2A do leczenia niewydolności serca - Google Patents

Pochodne androstanowe posiadające aktywność jako czyste lub w przeważającym stopniu czyste stymulatory SERCA2A do leczenia niewydolności serca

Info

Publication number
PL3805243T3
PL3805243T3 PL19202257.2T PL19202257T PL3805243T3 PL 3805243 T3 PL3805243 T3 PL 3805243T3 PL 19202257 T PL19202257 T PL 19202257T PL 3805243 T3 PL3805243 T3 PL 3805243T3
Authority
PL
Poland
Prior art keywords
pure
serca2a
stimulators
activity
treatment
Prior art date
Application number
PL19202257.2T
Other languages
English (en)
Inventor
Alberto Cerri
Patrizia Ferrari
Mara Ferrandi
Paolo BARASSI
Giuseppe Bianchi
Shin-Che HSU
Francesco Peri
Antonio ZAZA
Marcella ROCCHETTI
Andrea LURAGHI
Eleonora TORRE
Carlotta RONCHI
Original Assignee
Windtree Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Windtree Therapeutics, Inc. filed Critical Windtree Therapeutics, Inc.
Publication of PL3805243T3 publication Critical patent/PL3805243T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19202257.2T 2019-10-09 2019-10-09 Pochodne androstanowe posiadające aktywność jako czyste lub w przeważającym stopniu czyste stymulatory SERCA2A do leczenia niewydolności serca PL3805243T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19202257.2A EP3805243B1 (en) 2019-10-09 2019-10-09 Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure

Publications (1)

Publication Number Publication Date
PL3805243T3 true PL3805243T3 (pl) 2024-03-18

Family

ID=68242483

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19202257.2T PL3805243T3 (pl) 2019-10-09 2019-10-09 Pochodne androstanowe posiadające aktywność jako czyste lub w przeważającym stopniu czyste stymulatory SERCA2A do leczenia niewydolności serca

Country Status (16)

Country Link
US (2) US12503484B2 (pl)
EP (1) EP3805243B1 (pl)
JP (1) JP7805636B2 (pl)
KR (1) KR102976305B1 (pl)
CN (1) CN114466855A (pl)
AU (1) AU2020363865B2 (pl)
BR (1) BR112022003915A2 (pl)
CA (1) CA3149938A1 (pl)
DK (1) DK3805243T3 (pl)
ES (1) ES2970792T3 (pl)
FI (1) FI3805243T3 (pl)
IL (1) IL291412B2 (pl)
MX (2) MX2022003997A (pl)
PL (1) PL3805243T3 (pl)
TW (1) TWI859343B (pl)
WO (1) WO2021069570A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114409726B (zh) * 2022-01-24 2023-07-04 东华大学 桦木醇环烯烃衍生物及其用途和制备方法
WO2025128432A1 (en) * 2023-12-11 2025-06-19 Windtree Therapeutics, Inc. Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1175219A (en) * 1967-06-22 1969-12-23 Ici Ltd 3-Aminoalkoxycarbonylmethylene Steroid Derivatives
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
ES8706717A1 (es) * 1983-08-02 1987-07-01 Research Corp Metodo de preparar esteroides
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4221636C1 (de) 1992-07-01 1994-03-31 Sigma Tau Ind Farmaceuti Cyclopentanperhydrophenanthren-17beta-(3-furyl)-3-Derivate
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
AU706195B2 (en) 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
DE19633349A1 (de) * 1996-08-19 1998-02-26 Sigma Tau Ind Farmaceuti Neue 6-Hydroxy- und 6-Oxo-androstan-Derivate, die auf das kardiovaskuläre System wirken und pharmazeutische Zusammensetzungen, die diese enthalten
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CN1261791A (zh) 1997-07-02 2000-08-02 Sdg有限公司 诊断或治疗用途的靶向脂质体构建物
SE9704076D0 (sv) 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
KR20060123384A (ko) 2003-12-24 2006-12-01 가부시키가이샤 엘티티 바이오파마 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US20070082042A1 (en) 2004-08-06 2007-04-12 Deok-Hoon Park Multiple-layered liposome and preparation method thereof
EP1812074B1 (en) 2004-10-18 2010-12-29 Nitto Denko Corporation Intracellular peptide delivery
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
EP1993672B1 (en) * 2006-01-31 2012-01-25 The University of Toledo Use of cardiotonic steroids as Na/K-ATPase ligands for the treatment of the skin
TWI389917B (zh) 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
BRPI1012240A2 (pt) * 2009-03-23 2018-06-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. derivados de 5-beta, beta-14-androstana úteis para o tratamento de proteinúria, de glomeruloesclerose e de insuficiência renal
WO2014018375A1 (en) * 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
CN103315968B (zh) 2013-06-26 2015-04-01 中国生命药物治疗有限公司 一种注射用粉针剂及其制备方法
CN112118846B (zh) 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂

Also Published As

Publication number Publication date
WO2021069570A1 (en) 2021-04-15
IL291412B1 (en) 2025-08-01
KR20220079601A (ko) 2022-06-13
IL291412B2 (en) 2025-12-01
CA3149938A1 (en) 2021-04-15
TWI859343B (zh) 2024-10-21
FI3805243T3 (fi) 2024-02-07
US20230009312A1 (en) 2023-01-12
ES2970792T3 (es) 2024-05-30
KR102976305B1 (ko) 2026-06-12
EP3805243B1 (en) 2023-11-15
JP2022551165A (ja) 2022-12-07
JP7805636B2 (ja) 2026-01-26
AU2020363865A1 (en) 2022-02-24
DK3805243T3 (da) 2024-01-02
MX2025001193A (es) 2025-03-07
CN114466855A (zh) 2022-05-10
BR112022003915A2 (pt) 2022-08-23
AU2020363865B2 (en) 2026-07-02
US20260125415A1 (en) 2026-05-07
EP3805243A1 (en) 2021-04-14
US12503484B2 (en) 2025-12-23
IL291412A (en) 2022-05-01
MX2022003997A (es) 2022-04-26
TW202128182A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
IL278922A (en) Decentralized pacing system
IL272729A (en) A goal-driven workflow for the treatment of cardiac arrhythmias
MX2022014414A (es) Compuestos de pirimidinodiona contra estados cardiacos.
WO2015142001A3 (ko) 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
EP3242709A4 (en) Cardiac stimulation of atrial-ventricle pathways and/or associated tissue
EP3346915A4 (en) Systems, devices, components and methods for detecting the locations of sources of cardiac rhythm disorders in a patient's heart
EP3038540A4 (en) Cardiac tissue anchoring devices, methods, and systems for treatment of congestive heart failure and other conditions
MY203427A (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
ZA201804696B (en) Therapeutic use of inhibitors of t cell activation or stimulation
WO2015191886A3 (en) Systems and methods for treating cardiac arrhythmias
EP3003452A4 (en) Cardiac tissue penetrating devices, methods, and systems for treatment of congestive heart failure and other conditions
WO2014099633A3 (en) Inhibitors of the renal outer medullary potassium channel
MX379899B (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal
EP4025296A4 (en) HEART PACING SYSTEM
IL291412A (en) Androstane derivatives with activity as pure or mostly pure serca2a agonists for the treatment of heart failure
EP3846843A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEART DISEASES
IL275273A (en) An improved compound for the treatment of heart failure
IL280243A (en) Compounds similar to 17beta-heterocyclyl-digitalis for the treatment of heart failure
EP3813872A4 (en) COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
WO2013079048A3 (de) Implantierbare indifferente elektrode
HK40078461A (en) Treatment of acute heart failure
GB201916461D0 (en) Improvements in, or relating to, the treatment of by-products
PL3710043T3 (pl) Fgf10 do leczenia chorób serca
HK40058355A (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)